- Marketwired•2 hours ago
InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury
InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, has entered into an agreement with Pfizer Inc. , one of the world's premier biopharmaceutical ...
- Investor's Business Daily•2 hours ago
Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
- Business Wire•3 hours ago
Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer , previously treated with one or more ALK inhibitors.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.77 - 33.99|
|52 Week Range||29.83 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.87|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|